Interessenskonflikt. 1) Cytosorb Register Planung. 2) Studie Seraph Microbind: ExThera Medical. 3) Fan von Arbeitsgruppe PD Dr.
|
|
|
- Kristin Ellis
- 6 years ago
- Views:
Transcription
1 Interessenskonflikt 1) Cytosorb Register Planung 2) Studie Seraph Microbind: ExThera Medical 3) Fan von Arbeitsgruppe PD Dr. David, MHH
2 Cytokinelimination bei Sepsis JanT Kielstein Braunschweig
3 Cytokinelimination bei Sepsis 1) Sepsis unmet medical need 2) Cytokine in der Sepsis 3) Adsorber 4) Alternative Technologien
4 Cytokinelimination bei Sepsis 1) Sepsis unmet medical need 2) Cytokine in der Sepsis 3) Adsorber 4) Alternative Technologien
5 Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock KUMAR et al. Crit Care Med. 34(6): , 2006
6 From: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA 315(8): , 2016 SEPSIS: life threatening organ dysfunction caused ba a dysregulated host respone to infection.
7 From: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA 315(8): , 2016 organ dysfunction: acute change in total SOFA Score >2 points consequent to infection.
8 From: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA 315(8): , 2016
9 From: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA 315(8): , 2016
10 Liste der FDA /EMA zugelassenen Medikamente zur Therapie der Sepsis
11 Cytokinelimination bei Sepsis 1) Sepsis unmet medical need 2) Cytokine in der Sepsis 3) Adsorber 4) Alternative Technologien
12 Extracorporeal therapies in non-renal disease: treatment of sepsis and the peak concentration hypothesis RONCO et al. Blood Purif 22(1):164-74, 2004 Excess pro- and anti-inflammatory mediators removed by continuous combined therapies Unselective high efficiency extracorporeal therapies might remove excess of pro- and anti-inflammatory mediators diminishing the amplified inflammatory response and the immunoparalisis induced by cell hyporesponsiveness
13 The prognostic value of concomitant assessment of NTproCNP, C-reactive protein, procalcitonin and inflammatory cytokines in septic patients. TOMASIUK et al. Crit Care 18(3): 440, 2014
14 Cytokinelimination bei Sepsis 1) Sepsis unmet medical need 2) Cytokine in der Sepsis 3) Adsorber 4) Alternative Technologien
15 Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial (n=243) PAYEN et al. Intensive Care Med 41(6):975-84, 2015
16 Efficacy of polymyxin B-immobilized fiber hemoperfusion for patients with septic shock caused by Gram-negative bacillus infection SAITO et al. PLoS One 12(3):e , 2017
17 biocompatible, highly porous polymer bead designed to capture and adsorb cytokines (~10-50 kda)
18 Effect of extracorporeal cytokine removal on vascular barrier function in a septic shock patient DAVID et al. J Intensive Care 5:12, 2017
19 Effect of extracorporeal cytokine removal on vascular barrier function in a septic shock patient DAVID et al. J Intensive Care 5:12, 2017
20 Hemoadsorption by CytoSorb in septic patients: a case series (n=26) KOGELMANN et al. Critical Care 21(1):74, 2017
21 Hemoadsorption by CytoSorb in septic patients: a case series (n=26) KOGELMANN et al. Critical Care 21(1):74, 2017
22 Efficacy and cardiovascular tolerability of EDD in critically ill patients: a randomized controlled study KIELSTEIN et al. AJKD 43: , 2004 Norepinephrine dose at 0 h EDD CVVH μg/kg/min UF volume EDD L/12h CVVH L/24 h Norepinephrine dose at 12 h EDD CVVH μg/kg/min
23 Hemoadsorption by CytoSorb in septic patients: a case series (n=26) KOGELMANN et al. Critical Care 21(1):74, 2017
24 From: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) JAMA 315(8):
25 Effect of hemoadsorption during cardiopulmonary bypass surgery a blinded, randomized, controlled pilot study using a novel adsorbent (n=37) BERNARDI et al. Critical Care 20:96, 2016
26 Effect of hemoadsorption during cardiopulmonary bypass surgery a blinded, randomized, controlled pilot study using a novel adsorbent (n=37) BERNARDI et al. Critical Care 20:96, 2016
27 stay tuned
28 Cytokinelimination bei Sepsis 1) Sepsis unmet medical need 2) Cytokine in der Sepsis 3) Adsorber 4) Alternative Technologien
29 Plasma exchange SCHWARTZ et al. Journal of Clinical Apheresis 31: , 2016
30 Plasma exchange in treatment refractory septic shock : Presentation of a therapeutic add-on strategy DAVID et al. Med Klin Intensivmed Notfmed 112(1):42-46, 2017
31 Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial BUSUND et al. Intensive Care 28: , 2002
32 Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial BUSUND et al. Intensive Care 28: , 2002
33 Therapeutic Plasma Exchange Decreases Levels of Routinely Used Cardiac and Inflammatory Biomarkers TUTAREL et al. PLoS ONE 7(6): e38573, 2012
34 Effect of TPE on plasma levels and total removal of adipokines and inflammatory markers SCHMIDT et al. BMC Obesity 2:37, 2015
35
36 Therapeutic plasma exchange as rescue therapy in severe sepsis and septic shock: retrospective observational single-centre study of 23 patients HADEM et al. BMC Anesthesiol 7;14(1):24, 2014
37 Therapeutic plasma exchange as rescue therapy in severe sepsis and septic shock: retrospective observational single-centre study of 23 patients HADEM et al. BMC Anesthesiol 7;14(1):24, 2014
38 The prognostic value of ADAMTS13 deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation PEIGNE et al. Crit Care 18;17(6):R273, 2013
39 Randomized, prospective, multicenter, open-label, controlled, parallel-group trial investigating the efficacy of add-on plasmaexchange as an adjunctive strategy against septic shock with multiple organ dysfunction (EXCHANGE trial) PI: PD Dr. Sascha David Hannover Medical School, GERMANY
40 Safety and Performance Evaluation of the Seraph Microbind Affinity Blood Filter for Reducing Bacteremia in Patients on Hemodialysis
41
42 I will survive
pat hways Medtech innovation briefing Published: 29 November 2016 nice.org.uk/guidance/mib87
pat hways CytoSorb therapy for sepsis Medtech innovation briefing Published: 29 November 2016 nice.org.uk/guidance/mib87 Summary The technology described in this briefing is CytoSorb therapy. It is an
CASE SERIES IN POSTOPERATIVE CARDIAC SURGERY PATIENTS
2 nd International User Meeting October 2, 2015 Berlin Prof. Dr. Karl Träger Cardiosurgical ICU Dept. of Cardiac Anesthesiology University Hospital Ulm Albert-Einstein-Allee 23, 89081 Ulm GERMANY karl.traeger@uniklinik-ulm.de
Blood purification in sepsis
Blood purification in sepsis Joannes-Boyau O Dept of anesthesiology and intensive care, University Hospital of Bordeaux, France 1 Types of Blood Purification hemofilters regular pore size (MW < 40,000D)
PREVENTION OF RENAL FAILURE
1 st INTERNAT. CYTOSORB USER MEETING 2015 PREVENTION OF RENAL FAILURE DUE TO RHABDOMYOLYSIS xxx A CASE REPORT USING CYTOSORB xi CLAUS-GEORG KRENN / 16. III. 2015 CONFLICT OF INTEREST CGK 2012 - STRATEGIES
oxiris A single CRRT set with multiple benefits for managing critically ill patients with AKI Adsorption of inflammatory mediators
oxiris A single CRRT set with multiple benefits for managing critically ill patients with AKI Adsorption of inflammatory mediators Heparin-grafted for reduced thrombogenicity Supports renal function POWERED
Rationale for renal replacement therapy in ICU: indications, approaches and outcomes. Richard Beale
Rationale for renal replacement therapy in ICU: indications, approaches and outcomes Richard Beale RIFLE classification (ADQI group) 2004 Outcome AKIN classification Definition: Abrupt (within 48 hrs)
CytoSorb Therapy. Indications and Set-up
CytoSorb Therapy Indications and Set-up CytoSorb therapy REGAIN CONTROL The statements in this document do not constitute diagnostic or therapeutic recommendations. It is a best practice collection, based
Sepsis and AKI. Exploring their relationship and therapeutic role of extracorporeal inflammatory mediator removal
Sepsis and AKI Exploring their relationship and therapeutic role of extracorporeal inflammatory mediator removal 57042F AKI Sepsis Therapy Brochure_v2m.indd 1 02/06/2016 14:36 Overview Sepsis and AKI in
What is sepsis? RECOGNITION. Sepsis I Know It When I See It 9/21/2017
Sepsis I Know It When I See It September 15, 2017 Matthew Exline, MD MPH Medical Director, Medical ICU What is sepsis? I shall not today attempt further to define the kinds of material [b]ut I know it
Endothelium as a part of septic Multiple Organ Dysfunction Syndrome (MODS)-is endocan an answer?
Endothelium as a part of septic Multiple Organ Dysfunction Syndrome (MODS)-is endocan an answer? Małgorzata Lipinska-Gediga Department of Anaesthesiology and Intensive Therapy Medical University Wroclaw,
582:2 )8102( Knaup et al. Critical Care https://doi.org/10.1186/s13054-018-2220-9 RESEARCH Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing
Disclosures. Objectives. Procalcitonin: Pearls and Pitfalls in Daily Practice
Procalcitonin: Pearls and Pitfalls in Daily Practice Sarah K Harrison, PharmD, BCCCP Clinical Pearl Disclosures The author of this presentation has no disclosures concerning possible financial or personal
Towards Precision Medicine in Sepsis Patients: Are We Close?
Towards Precision Medicine in Sepsis Patients: Are We Close? CRRT San Diego 2018 Peter Pickkers Department of Medicine Radboud university medical centre, Nijmegen No LPS circulating (n=55) P < 0.05 LPS
OHSU. Update in Sepsis
Update in Sepsis Jonathan Pak, MD June 1, 2017 Structure of Talk 1. Sepsis-3: The latest definition 2. Clinical Management - Is EGDT dead? - Surviving Sepsis Campaign Guidelines 3. A novel therapy: Vitamin
Intraoperative application of Cytosorb in cardiac surgery
Intraoperative application of Cytosorb in cardiac surgery Dr. Carolyn Weber Heart Center of the University of Cologne Dept. of Cardiothoracic Surgery Cologne, Germany SIRS & Cardiopulmonary Bypass (CPB)
The Usefulness of Sepsis Biomarkers. Dr Vineya Rai Department of Anesthesiology University of Malaya
The Usefulness of Sepsis Biomarkers Dr Vineya Rai Department of Anesthesiology University of Malaya 1 What is Sepsis? Whole Body Inflammatory State + Infection 2 Incidence and Burden of Sepsis in US In
Systemic Inflammatory Response Syndrome in Heart Surgery: New possibilities for treatment through the use of a cytokine adsorber during ECC?
Systemic Inflammatory Response Syndrome in Heart Surgery: New possibilities for treatment through the use of a cytokine adsorber ABSTRACT The ECC is still the key technology in the performance of cardiac
BIOMARKERS IN SEPSIS
BIOMARKERS IN SEPSIS Dr. Syed Ghulam Mogni Mowla Assistant Professor, Medicine, DMC BSMCON 17 WHY WE NEED TO KNOW Sepsis and its complications are a common cause of infectious disease illness and mortality
LJPC-501 Market Opportunity
LJPC-501 Market Opportunity NASDAQ: LJPC July 2015 Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995.
What the ED clinician needs to know about SEPSIS - 3. Anna Morgan Consultant EM Barts Health
What the ED clinician needs to know about SEPSIS - 3 Anna Morgan Consultant EM Barts Health Aims: (1) To review the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) (2)
Current State of Pediatric Sepsis. Jason Clayton, MD PhD Pediatric Critical Care 9/19/2018
Current State of Pediatric Sepsis Jason Clayton, MD PhD Pediatric Critical Care 9/19/2018 Objectives Review the history of pediatric sepsis Review the current definition of pediatric sepsis Review triage
Sepsis Management: Past, Present, and Future
Sepsis Management: Past, Present, and Future Benjamin Ferrell, MD Tennessee ACP Meeting October 28, 2017 Learning Objectives Identify the most updated definition and clinical criteria for sepsis Describe
Physiology of Blood Purification: Dialysis & Apheresis. Outline. Solute Removal Mechanisms in RRT
Physiology of Blood Purification: Dialysis & Apheresis Jordan M. Symons, MD University of Washington School of Medicine Seattle Children s Hospital Outline Physical principles of mass transfer Hemodialysis
Disclosures Paul Walker MD PhD FRCSC
1 ` Disclosures Paul Walker MD PhD FRCSC CEO Spectral Medical 2001-present Inaugural Critical Care Program Director - University of Toronto Chief of Surgery - University Health Network 1991-1999 COO Toronto
Extracorporeal membrane oxygenation and cytokine adsorption
Review Article Extracorporeal membrane oxygenation and cytokine adsorption Thomas Datzmann, Karl Tra ger Department of Cardiac Anesthesiology, University Hospital Ulm, Ulm, Germany Contributions: (I) Conception
Severe sepsis, defined as sepsis with acute organ dysfunction,
Review Article Blood Purification and Mortality in Sepsis: A Meta-Analysis of Randomized Trials* Feihu Zhou, MD, PhD 1,2 ; Zhiyong Peng, MD, PhD 1 ; Raghavan Murugan, MD, MS, FRCP 1 ; John A. Kellum, MD,
Continuous Hemodiafiltration with a Cytokine-Adsorber During Sepsis
Continuous Hemodiafiltration with a Cytokine-Adsorber During Sepsis Department of Plastic and Hand Surgery, Burn Unit, Bergmannstrost Halle, Germany Director: Professor Frank Siemers Khosrow Houschyar,
Initial Resuscitation of Sepsis & Septic Shock
Initial Resuscitation of Sepsis & Septic Shock Dr. Fatema Ahmed MD (Critical Care Medicine) FCPS (Medicine) Associate professor Dept. of Critical Care Medicine BIRDEM General Hospital Is Sepsis a known
EFFECT OF EARLY VASOPRESSIN VS NOREPINEPHRINE ON KIDNEY FAILURE IN PATIENTS WITH SEPTIC SHOCK. Alexandria Rydz
EFFECT OF EARLY VASOPRESSIN VS NOREPINEPHRINE ON KIDNEY FAILURE IN PATIENTS WITH SEPTIC SHOCK Alexandria Rydz BACKGROUND- SEPSIS Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated
Updates On Sepsis Updates based on 2016 updates on sepsis from The International Surviving Sepsis Campaign
Updates On Sepsis Updates based on 2016 updates on sepsis from The International Surviving Sepsis Campaign Dr. Joseph K Erbe, DO Medical Director Hospitalist Division of Medicine Objectives 1. Review the
R2R: Severe sepsis/septic shock. Surat Tongyoo Critical care medicine Siriraj Hospital
R2R: Severe sepsis/septic shock Surat Tongyoo Critical care medicine Siriraj Hospital Diagnostic criteria ACCP/SCCM consensus conference 1991 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
INTENSIVE CARE MEDICINE CPD EVENING. Dr Alastair Morgan Wednesday 13 th September 2017
INTENSIVE CARE MEDICINE CPD EVENING Dr Alastair Morgan Wednesday 13 th September 2017 WHAT IS NEW IN ICU? (RELEVANT TO ANAESTHETISTS) Not much! SURVIVING SEPSIS How many deaths in England were thought
Advancements in Sepsis
Objectives Advancements in Sepsis Brian Gilbert, PharmD PGY-1 Pharmacy Resident Jackson Memorial Hospital 3/13/2016 www.fshp.org Pharmacist objectives Review recent updates in resuscitation strategies
Sepsis newer therapies in management. Raghava Rao G SR,Dept of pulmonology & critical care
Sepsis newer therapies in management Raghava Rao G SR,Dept of pulmonology & critical care Topics of discussion Sepsis pathophysiology Newer biomarkers Newer treatment options Immunomodulators Ivig/GM CSF/Steroids/PD-1,PD-L1/Heparin/TLR
A single-center experience with resin adsorption hemoperfusion combined with continuous veno-venous hemofiltration for septic shock patients
Available online at www.medicinescience.org ORIGINAL RESEARCH Medicine Science International Medical Journal Medicine Science 09; ( ): A single-center experience with resin adsorption hemoperfusion combined
Sepsis and Antimcrobial Stewardship: Are they really mutually Exclusive?
Sepsis and Antimcrobial Stewardship: Are they really mutually Exclusive? DR KATE ADAMS CONSULTANT INFECTIOUS DISEASES HULL AND EAST YORKSHIRE NHS TRUST AMS Sepsis No! At least not if the sepsis programme
The International CytoSorb-Registry
The International CytoSorb-Registry Coordinating investigator Overall coordination Prof. Dr. Frank M. Brunkhorst. Jena University Hospital Financial support CytoSorbents Europe GmbH Ways to find truth
Biomarkers in sepsis. Dr S Omar University of Witwatersrand CHBAH Bara ICU
Biomarkers in sepsis Dr S Omar University of Witwatersrand CHBAH Bara ICU Procalcitonin PCT biomarker 1993- described as a sepsis associated protein Identical to the precursor protein of calcitonin which
Comparing RRT Modalities: Does It Matter What You Use If The Job Is Done?
Comparing RRT Modalities: Does It Matter What You Use If The Job Is Done? Sean M Bagshaw, MD, MSc Division of Critical Care Medicine University of Alberta Disclosure Consulting: Alere, Baxter, Gambro,
RENAL FAILURE IN ICU. Jo-Ann Vosloo Department Critical Care SBAH
RENAL FAILURE IN ICU Jo-Ann Vosloo Department Critical Care SBAH DEFINITION: RIFLE criteria Criteria for initiation of RRT Modes of RRT (options) CRRT = continuous renal replacement therapy SCUF : Ultra-filtration
doi: /ams2.382
Acute Medicine & Surgery 2019; 6: 60 67 doi: 10.1002/ams2.382 Original Article The 28-day survival rates of two cytokine-adsorbing hemofilters for continuous renal replacement therapy: a single-center
Zacks Small-Cap Research
Zacks Small-Cap Research October 26, 2017 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 CytoSorbents Corporation (CTSO-NASDAQ) CTSO: Additional
LEVELS OF IMMUNOSUPPRESSIVE DRUGS DURING CYTOSORB TREATMENT IN-VITRO STUDY TO COME
LEVELS OF IMMUNOSUPPRESSIVE DRUGS DURING CYTOSORB TREATMENT IN-VITRO STUDY TO COME 2 nd International CytoSorb User s Meeting Zoller et al, 2015 Conclusions: because of the possible adsorption of antibiotics
Sepsi: nuove definizioni, approccio diagnostico e terapia
GIORNATA MONDIALE DELLA SEPSI DIAGNOSI E GESTIONE CLINICA DELLA SEPSI Giovedì, 13 settembre 2018 Sepsi: nuove definizioni, approccio diagnostico e terapia Nicola Petrosillo Società Italiana Terapia Antiinfettiva
CytoSorbentsTM. CytoSorb Therapy: Evidence in septic and vasoplegic shock. 1 st Edition. Studies Case series Selected case reports
CytoSorbentsTM CytoSorb Therapy: Evidence in septic and vasoplegic shock st Edition CytoSorb Therapy REGAIN CONTROL Studies Case series Selected case reports TABLE OF CONTENTS TABLE OF CONTENTS STUDIES
Is nosocomial infection the major cause of death in sepsis?
Is nosocomial infection the major cause of death in sepsis? Warren L. Lee, MD PhD, FRCPC Department of Medicine University of Toronto There are no specific therapies for sepsis the graveyard for pharmaceutical
5/27/2016. Pediatric Grand Rounds University of TX Health Science Center at San Antonio SEPSIS UPDATE DISCLOSURE JOIN IN OBJECTIVES WHY SEPSIS ORIGIN
DISCLOSURE I have no relevant relationships with financial or commercial companies to disclose SEPSIS UPDATE EARLY RECOGNITION THROUGH ADVANCED THERAPIES Christin A. Carroll, MD, MS, FAAP Clinical Instructor
Polymyxin B Hemoperfusion in Pneumonic Septic Shock Caused by Gram-Negative Bacteria
Korean J Crit Care Med 2015 August 30(3):171-175 / ISSN 2383-4870 (Print) ㆍ ISSN 2383-4889 (Online) Case Report Polymyxin B Hemoperfusion in Pneumonic Septic Shock Caused by Gram-Negative Bacteria Jung-Wan
Drug dosing in patients with acute kidney injury
Drug dosing in patients with acute kidney injury They don t know what they are doing Jan Jan T. T. Kielstein Department of of Nephrology and and Hypertension Medical School School Hannover Drug dosing
Septic Shock. Rontgene M. Solante, MD, FPCP,FPSMID
Septic Shock Rontgene M. Solante, MD, FPCP,FPSMID Learning Objectives Identify situations wherein high or low BP are hemodynamically significant Recognize complications arising from BP emergencies Manage
Thomas Datzmann, Karl Träger
Editorial What about prognostic outcome parameters in patients with acute respiratory distress syndrome (ARDS) treated with veno-venous extracorporeal membrane oxygenation (VV-ECMO)? Thomas Datzmann, Karl
Fluid Management in Critically Ill AKI Patients
Fluid Management in Critically Ill AKI Patients Sang Kyung Jo, MD, PhD Department of Internal Medicine Korea University Medical College KO/MG31/15-0017 Outline Fluid balance in critically ill patients:
Research paper 45. Address: Department of Anaesthesiology, University of Erlangen-Nuremburg, Krankenhausstr. 12, D Erlangan, Germany.
Research paper 45 Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS Michael Meisner, Klaus Tschaikowsky,
Timing, Dosing and Selecting of modality of RRT for AKI - the ERBP position statement
Timing, Dosing and Selecting of modality of RRT for AKI - the ERBP position statement Prof. Dr. Achim Jörres Dept. of Nephrology and Medical Intensive Care Charité University Hospital Campus Virchow Klinikum
Septic shock secondary to β-hemolytic streptococcusinduced necrotizing fasciitis treated with a novel cytokine adsorption therapy
Int J Artif Organs 2014; 37 ( 00) : 000-000 DOI: 10.5301/ijao.5000315 SHORT COMMUNICATION Septic shock secondary to β-hemolytic streptococcusinduced necrotizing fasciitis treated with a novel cytokine
Sepsis: Identification and Management in an Acute Care Setting
Sepsis: Identification and Management in an Acute Care Setting Dr. Barbara M. Mills DNP Director Rapid Response Team/ Code Resuscitation Stony Brook University Medical Center SEPSIS LECTURE NPA 2018 OBJECTIVES
Prehospital recognition of sepsis Christopher W. Seymour, MD MSc
Prehospital recognition of sepsis Christopher W. Seymour, MD MSc The CRISMA Center Assistant Professor of Critical Care Medicine & Emergency Medicine University of Pittsburgh School of Medicine Disclosures
SEPSIS & SEPTIC SHOCK
SEPSIS & SEPTIC SHOCK DISCLOSURE Relevant relationships with commercial entities none Potential for conflicts of interest within this presentation none Steps taken to review and mitigate potential bias
Commentary Recent evolution of renal replacement therapy in the critically ill patient Claudio Ronco
Commentary Recent evolution of renal replacement therapy in the critically ill patient Claudio Ronco Department of Nephrology, St Bortolo Hospital, Vicenza, Italy Corresponding author: Claudio Ronco, cronco@goldnet.it
Adsorbtion of Cytokines Early in Septic Shock: the ACESS trial
Adsorbtion of Cytokines Early in Septic Shock: the ACESS trial Prof. Zsolt Molnár zsoltmolna@gmail.com Department of Anaesthesia and Intensive Care University of Szeged Hungary Pathophysiology Local insult
Importance of kinetics of procalcitonin in septic patients. János Fazakas MD, PhD Semmelweis University, Department of Transplantation and Surgery
Importance of kinetics of procalcitonin in septic patients János Fazakas MD, PhD Semmelweis University, Department of Transplantation and Surgery Host pathogen interactions the innate and the adaptive
JAMA. 2016;315(8): doi: /jama
JAMA. 2016;315(8):801-810. doi:10.1001/jama.2016.0287 SEPSIS 3 life-threatening organ dysfunction caused by a dysregulated host response to infection organ dysfunction: an increase in the SOFA
Early Recognition and Timely Management of Sepsis Amid Changes in Definitions
Early Recognition and Timely Management of Sepsis Amid Changes in Definitions Tze Shien Lo, MD, FACP Chief, Infectious Disease Service Fargo VA Medical Center Professor of Medicine UND School of Medicine
Proceedings 2nd International Users Meeting, Berlin, Germany October 2nd, 2015
Proceedings 2 nd International Users Meeting, Berlin, Germany October 2 nd, 2015 CYTOSORB - THERAPY REGAIN CONTROL All presentations are available in the CytoSorbents Community Area. Download on cytosorb-therapy.com/eventreview
NE refractoriness: From Definition To Treatment... Prof. Alain Combes
NE refractoriness: From Definition To Treatment... Prof. Alain Combes Service de Réanimation ican, Institute of Cardiometabolism and Nutrition Hôpital Pitié-Salpêtrière, AP-HP, Paris Université Pierre
CURRENT GUIDELINES FOR SEPSIS MANAGEMENT
HELLENIC SEPSIS STUDY GROUP www.sepsis.gr CURRENT GUIDELINES FOR SEPSIS MANAGEMENT Evangelos J. Giamarellos-Bourboulis, MD, PhD Associate Professor of Medicine 4 th Department of Internal Medicine, National
F12 Sorbent Based and Hybrid Therapies for Extracorporeal Support Continuous Hemodiafiltration with Cytokine-Adsorbing Hemofilters (CAH-CHDF)
F12 Sorbent Based and Hybrid Therapies for Extracorporeal Support Continuous Hemodiafiltration with Cytokine-Adsorbing Hemofilters (CAH-CHDF) Hiroyuki Hirasawa, MD, PhD Professor Emeritus, Department of
The syndrome formerly known as. Severe Sepsis. James Rooks MD. Coordinator of critical care education OU College of Medicine, Tulsa
The syndrome formerly known as Severe Sepsis James Rooks MD Coordinator of critical care education OU College of Medicine, Tulsa Disclosures I have no actual or practical conflicts of interest in relation
CORTICOSTEROID USE IN SEPTIC SHOCK THE ONGOING DEBATE DIEM HO, PHARMD PGY1 PHARMACY RESIDENT VALLEY BAPTIST MEDICAL CENTER BROWNSVILLE
CORTICOSTEROID USE IN SEPTIC SHOCK THE ONGOING DEBATE DIEM HO, PHARMD PGY1 PHARMACY RESIDENT VALLEY BAPTIST MEDICAL CENTER BROWNSVILLE 1 ABBREVIATIONS ACCP = American College of Chest Physicians ARF =
Procalcitonin YUKON KUSKOKWIM HEALTH CORPORATION PRESENTED BY: CURT BUCHHOLZ, MD AUGUST 2017
Procalcitonin YUKON KUSKOKWIM HEALTH CORPORATION PRESENTED BY: CURT BUCHHOLZ, MD AUGUST 2017 Procalcitonin (PCT) PCT isbeing studied as a biomarker for infection PCT consists of 116 amino
SEPSIS-3: THE NEW DEFINITIONS
SEPSIS-3: THE NEW DEFINITIONS WHAT THEY SHOULD MEAN TO YOU MERVYN SINGER BLOOMSBURY INSTITUTE OF INTENSIVE CARE MEDICINE UNIVERSITY COLLEGE LONDON, UK https://www.youtube.com/watch?v=1s8l5d2xr6w IN THE
Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill
Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill Joe Palumbo PGY-2 Critical Care Pharmacy Resident Buffalo General Medical Center Disclosures
Update in Critical Care Medicine
Update in Critical Care Medicine Michael A. Gropper, MD, PhD Professor and Executive Vice Chair Department of Anesthesia and Perioperative Care Director, Critical Care Medicine UCSF Disclosure None Update
What is the Role of Albumin in Sepsis? An Evidenced Based Affair. Justin Belsky MD PGY3 2/6/14
What is the Role of Albumin in Sepsis? An Evidenced Based Affair Justin Belsky MD PGY3 2/6/14 Microcirculation https://www.youtube.com/watch?v=xao1gsyur7q Capillary Leak in Sepsis Asking the RIGHT Question
Olistic Approach to Treatment Adequacy in AKI
Toronto - Canada, 2014 Olistic Approach to Treatment Adequacy in AKI Claudio Ronco, MD Department of Nephrology, St. Bortolo Hospital, International Renal Research Institute Vicenza - Italy 1) RRT
Managing Patients with Sepsis
Managing Patients with Sepsis Diagnosis; Initial Resuscitation; ARRT Initiation Prof. Achim Jörres, M.D. Dept. of Nephrology and Medical Intensive Care Charité University Hospital Campus Virchow Klinikum
International Users Meeting. Proceedings. 3 rd International CytoSorb Users Meeting Brussels, Belgium, March 14 th, 2016
3 rd International Users Meeting Proceedings 3 rd International CytoSorb Users Meeting Brussels, Belgium, March 14 th, 216 All presentations are available in the CytoSorbents Community Area. CYTOSORB -
Text-based Document. Implications of the Sepsis-3 Definition on Nursing Research and Practice. Authors Peach, Brian C. Downloaded 5-Jul :03:48
The Henderson Repository is a free resource of the Honor Society of Nursing, Sigma Theta Tau International. It is dedicated to the dissemination of nursing research, researchrelated, and evidence-based
Prof Patrick Honoré,MD, PhD,FCCM Intensivist-Nephrologist
Pro-Con Debate on High Volume Hemofiltration :Burial or Ressurection? The Pro Position 1.-Why Moving From Dose To Membranes? 4.-AN69 Oxiris LPS Adsorptive Membranes in Sepsis 2.- High Cut-Off Membranes
higher dose with progress in technical equipment. Continuous Dialysis: Dose and Antikoagulation. prescribed and delivered
1 2 Continuous Dialysis: Dose and Antikoagulation higher dose with progress in technical equipment Comparison of pump-driven and spontaneous continuous haemofiltration in postoperative acute renal failure.
Controversies in Hospital Medicine: Critical Care. Vasopressors, Steroids, and Insulin Therapy
Controversies in Hospital Medicine: Critical Care Vasopressors, Steroids, and Insulin Therapy Douglas Fish, Pharm.D. Professor of Pharmacy, University of Colorado Denver Clinical Specialist in Critical
Resuscitation Symposium Resuscitation Literature Update. Abdullah Al Reesi, MD, MSc, FACEP, FRCPC Sr. Consultant and HoD SQUH
Resuscitation Symposium Resuscitation Literature Update Abdullah Al Reesi, MD, MSc, FACEP, FRCPC Sr. Consultant and HoD SQUH Objectives Review recent articles in sepsis New sepsis definition High versus
Assessing thrombocytopenia in the intensive care unit: The past, present, and future
Assessing thrombocytopenia in the intensive care unit: The past, present, and future Ryan Zarychanski MD MSc FRCPC Sections of Critical Care and of Hematology, University of Manitoba Disclosures FINANCIAL
SEPSIS MANAGEMENT. Abdulhadi Tashkandi, MD, FRCP(c) Assistant Prof. Of Medicine Head of E.D. PMBAH-National Guard hospital Al-Madinah Al-Munawarah
SEPSIS MANAGEMENT Abdulhadi Tashkandi, MD, FRCP(c) Assistant Prof. Of Medicine Head of E.D. PMBAH-National Guard hospital Al-Madinah Al-Munawarah goals Treatment of pts. with septic shock consists of
Chapter 5: Sepsis Stephen Lo
Chapter 5: Sepsis Stephen Lo Introduction Sepsis and its consequence are the bread and butter of intensive care medicine and management of it is time critical. This chapter will discuss the definitions,
Nothing to disclose 9/25/2017
Jessie O Neal, PharmD, BCCCP Critical Care Clinical Pharmacist University of New Mexico Hospital New Mexico Society of Health-System Pharmacists 2017 Balloon Fiesta Symposium Nothing to disclose 1 Explain
Fluid Resuscitation and Monitoring in Sepsis. Deepa Gotur, MD, FCCP Anne Rain T. Brown, PharmD, BCPS
Fluid Resuscitation and Monitoring in Sepsis Deepa Gotur, MD, FCCP Anne Rain T. Brown, PharmD, BCPS Learning Objectives Compare and contrast fluid resuscitation strategies in septic shock Discuss available
9/25/2017. Nothing to disclose
Nothing to disclose Jessie O Neal, PharmD, BCCCP Critical Care Clinical Pharmacist University of New Mexico Hospital New Mexico Society of Health-System Pharmacists 2017 Balloon Fiesta Symposium Explain
Staging Sepsis for the Emergency Department: Physician
Staging Sepsis for the Emergency Department: Physician Sepsis Continuum 1 Sepsis Continuum SIRS = 2 or more clinical criteria, resulting in Systemic Inflammatory Response Syndrome Sepsis = SIRS + proven/suspected
When and how to start RRT in critically ill patients? Intensive Care Training Program Radboud University Medical Centre Nijmegen
When and how to start RRT in critically ill patients? Intensive Care Training Program Radboud University Medical Centre Nijmegen Case history (1) 64 Hypertension 2004 AVR 2009 Paravalvular leak - dilated
Basics from anatomy and physiology classes Local tissue reactions
Septicaemia & SIRS Septicaemia is a life-threatening condition that arises when the physical reaction to an infection, causes damage to tissue and organs Basics from anatomy and physiology classes Local
Blood Purification for Sepsis - Which Molecules Should We Remove Endotoxin or Cytokines?
Plenary 5 MINI SYMPOSIA Challenges and Controversies in Renal Support and CRRT Blood Purification for Sepsis - Which Molecules Should We Remove Endotoxin or Cytokines? Hiroyuki Hirasawa, MD, PhD Professor
Steroids in ARDS: if, when, how much? John Fowler, MD, FACEP Dept. of Emergency Medicine Kent Hospital, İzmir, Türkiye
Steroids in ARDS: if, when, how much? John Fowler, MD, FACEP Dept. of Emergency Medicine Kent Hospital, İzmir, Türkiye Steroids in ARDS: conclusion Give low-dose steroids if indicated for another problem
AN INTRODUCTION TO EXTRACORPOREAL BLOOD PURIFICATION IN CRITICAL ILLNESS. Proceedings of Singapore Healthcare Volume 21 Number
AN INTRODUCTION TO EXTRACORPOREAL BLOOD PURIFICATION IN CRITICAL ILLNESS Proceedings of Singapore Healthcare Volume 21 Number 2 2012 本檔僅供內部教學使用檔案內所使用之照片之版權仍屬於原期刊公開使用時, 須獲得原期刊之同意授權 Mechanisms of Extracorporeal
CytoSorbents Corporation (NASDAQ: CTSO) A Leader in Critical Care Immunotherapy Q Earnings Conference Call November 13, 2015
CytoSorbents Corporation (NASDAQ: CTSO) A Leader in Critical Care Immunotherapy Q3 2015 Earnings Conference Call November 13, 2015 Safe Harbor Statement Statements in this presentation regarding CytoSorbents
ECMO for Refractory Septic Shock Prof. Alain Combes
ECMO for Refractory Septic Shock Prof. Alain Combes Service de Réanimation ican, Institute of Cardiometabolism and Nutrition Hôpital Pitié-Salpêtrière, AP-HP, Paris Université Pierre et Marie Curie, Paris
4/5/2018. Update on Sepsis NIKHIL JAGAN PULMONARY AND CRITICAL CARE CREIGHTON UNIVERSITY. I have no financial disclosures
Update on Sepsis NIKHIL JAGAN PULMONARY AND CRITICAL CARE CREIGHTON UNIVERSITY I have no financial disclosures 1 Objectives Why do we care about sepsis Understanding the core measures by Centers for Medicare
changing the diagnosis and management of acute kidney injury
changing the diagnosis and management of acute kidney injury NGAL NGAL is a novel biomarker for diagnosing acute kidney injury (AKI). The key advantage of NGAL is that it responds earlier than other renal
Renal Replacement Therapy in Acute Renal Failure
CHAPTER 82 Renal Replacement Therapy in Acute Renal Failure R. Deshpande Introduction Acute renal failure (ARF) is defined as an abrupt decrease in renal function sufficient to result in retention of nitrogenous